52 Week Low Stocks Based on a Self-learning Algorithm: Returns up to 653.33% in 3 Months

52 Week Low Stocks

The 52 Week Low Stocks Package is designed for investors and analysts who need predictions for stocks currently at their 52-week low price level, offering the best market opportunities based on algo-trading. It includes 20 stocks with bullish and bearish signals and indicates the best stocks to invest in:

  • 52 Weeks Low Top 10 stocks for the long position
  • 52 Weeks Low Top 10 stocks for the short position

52 Week Low Stocks
Package Name: 52 Week Low Stocks
Recommended Positions: Long
Forecast Length: 3 Months (4/3/2020 – 7/4/2020)
I Know First Average: 100.7%
52 Week Low Stocks
52 Week Low Stocks chart

Several predictions in this 3 Months forecast saw significant returns. The algorithm had correctly predicted 9 out 10 stock movements. The greatest return came from CLDX at 653.33%. ABMD, and ADSK had notable returns of 84.14% and 75.23%. The package itself saw an overall return of 100.7%, providing investors with a 76.83% premium above the S&P 500’s return of 23.87% for the same time period.

Celldex Therapeutics, Inc., incorporated on December 9, 1983, is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. The Company is using the technologies to develop targeted immunotherapeutics consisting of protein-based molecules, such as vaccines, antibodies and antibody-drug conjugates that are used to treat specific types of cancer or other diseases. The Company’s lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is in clinical studies for the treatment of glioblastoma patients that express a specific cancer marker known as type III epidermal growth factor receptor mutation (EGFRvIII). Its Glembatumumab vedotin (also referred to as CDX-011) is a targeted antibody-drug conjugate for the treatment of metastatic melanoma. Its Varlilumab (also referred to as CDX-1127) is an immune modulating antibody that is designed to enhance a patient’s immune response against their cancer. The Company’s earlier stage drug candidates in clinical development include CDX-1401, which is a targeted immunotherapeutic aimed at antigen presenting cells (APC) for cancer indications and CDX-301, which is an immune cell mobilizing agent and dendritic cell growth factor. The Company’s pipeline also includes CDX-0158 and CDX-3379.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.